Pascal Soriot is still hard at work in patching up AstraZeneca's (NYSE:AZN) battered pipeline and five-year profit prospects. Following the announcement of an agreement to acquire Omthera (Nasdaq:OMTH) to boost the company's cardiovascular drug business, AstraZeneca announced Monday that it was acquiring development-stage COPD drug developer Pearl Therapeutics. While AstraZeneca does not appear to be buying a future blockbuster, the deal should be a relatively low-risk way to boost the company's important respiratory drug franchise and offset some of the downside risk to the five-year revenue and profit outlook.

The Deal To Be
AstraZeneca has agreed to acquire Pearl Therapeutics for up to $1.15 billion. Like the Omthera deal, this transaction is structured in such a way that AstraZeneca shareholders will be partially shielded from clinical failures (a very sensitive point given a string of pipeline failures). About half of the headline number ($560 million) will be paid upfront, while $450 million is tied to clinical milestones and $140 million is tied to sales milestones.

SEE: Analyzing An Acquisition Announcement

What AstraZeneca Is Buying
AstraZeneca is acquiring Pearl Therapeutics for its COPD pipeline. Pearl's PT003 is a LAMA/LABA combination in Phase III studies. Early study results showed solid efficacy relative to Boehringer's Spiriva, and a US filing could come in 2015.

While there are all of the normal risks that PT003 could fail in Phase III testing, there are other potential issues with this product. First, it will be the fifth combo to market (assuming everybody else stays on track) after GlaxoSmithKline (NYSE:GSK) or Theravance (Nasdaq:THRX), Novartis (NYSE:NVS), Forest Labs (NYSE:FRX), and Boeringher. Second, the twice-daily dosing (relative to Glaxo's Anoro, which is once-daily) could be a limiting competitive factor.

On the other hand, PT003 is given with a pressured metered dose inhaler (pMDI) that could make administration easier for some patients. Moreover, the drug is made using a novel co-suspension formulation technology that could have broader potential use in AstraZeneca's hands. It's also important to note that AstraZeneca had no LAMA in late-stage development, and this drug could be a valuable bridge to the pipeline MABA drug AZD2115.

It's also worth noting that Pearl has two other combinations in early-stage development, one a LAMA/LABA/ICS combo and the other a LAMA/ICS combo.

Home Runs Matter Less Than Avoiding Strike-Outs
This isn't likely to be the sort of deal that changes AstraZeneca's fortunes like Cougar Biotechnology (developer of Zytiga) did for Johnson & Johnson (NYSE:JNJ). Instead, it looks like the sort of deal that could lift AstraZeneca's batting average and get actual products out into the actual market. That fits in with the early pattern being established by new CEO Soriot – forget swinging for the fences, or at least until the company has a solid foundation beneath its feet once again. It's a strategy that helped fix Sanofi (NYSE:SNY) and it should work for AstraZeneca as well.

There's still room for bears to complain about this deal. For instance, it is fair to ask why, in a pretty hot market for biotech, Pearl chose to go with a buyout instead of an IPO. I frankly think this is a better move for Pearl - biotech market could have cooled during the IPO process, and investors would have asked pointed questions about Pearl's positioning as fifth-in-class – but this isn't going to sway AstraZeneca skeptics.

SEE: Cashing In On Corporate Restructuring

The Bottom Line
I like this deal better than the prior deal for Omthera, as I believe there's less controversy about LAMA/LABA's place in treating COPD than pharma-grade fish oil in cardiovascular disease. In both cases the deals do not massively change my long-term revenue and free cash flow (FCF) assumptions, but they do improve the probability-adjusted figures and the overall risk profile of AstraZeneca is heading in a better direction.
While I think investors are going to have to wait a while to see the proof in the financials that AstraZeneca is in better shape, a lot of the potential gains in the stock will be gone by the time that arrives. Accordingly, while I do see plenty of risk in AstraZeneca, it does offer some of the most significant capital appreciation potential within the Big Pharma sector.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Markets

    Relative Valuation Of Stocks Can Be A Trap

    This method of valuing a company can make it look like a bargain when it is not.
  2. Investing Basics

    DCF Valuation: The Stock Market Sanity Check

    Calculate whether the market is paying too much for a particular stock.
  3. Investing

    Using DCF In Biotech Valuation

    Valuing firms in this sector can seem like a black art, but there is a systematic way to pin a price on potential.
  4. Bonds & Fixed Income

    Equity Valuation In Good Times And Bad

    Learn how to filter out the noise of the market place in order to find a solid way of determing a company's value.
  5. Markets

    Investment Valuation Ratios

    Learn about per share data, price/book value ratio, price/cash flow ratio, price/earnings ratio, price/sales ratio, dividend yield and the enterprise multiple.
  6. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  7. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  8. Active Trading Fundamentals

    The Biggest Private Equity Firms in Los Angeles

    Learn why Los Angeles is a thriving market for private equity, and identify the five largest private equity firms operating in the city.
  9. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  10. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Nasdaq Biotech

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Poison Put

    A takeover defense strategy in which the target company issues ...
  3. Assented Stock

    A share of stock owned by a shareholder who has agreed to a takeover.
  4. Back-End Plan

    An anti-acquisition strategy in which the target company provides ...
  5. Voting Poison Pill Plan

    An anti-takeover strategy in which the company being targeted ...
  6. Enterprise Value (EV)

    A measure of a company's value, often used as an alternative ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. What role does the agency problem play in the modern Health Care industry?

    Agency problems vary from health care system to health care system, and not all economists agree on the degree and desirability ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!